HC Wainwright Reiterates “Buy” Rating for Keros Therapeutics (NASDAQ:KROS)

Keros Therapeutics (NASDAQ:KROS)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $40.00 price target on the stock. HC Wainwright’s target price indicates a potential upside of 292.54% from the stock’s current price.

Several other analysts have also recently weighed in on KROS. William Blair cut Keros Therapeutics from an “outperform” rating to a “market perform” rating in a report on Thursday, December 12th. Cantor Fitzgerald lowered shares of Keros Therapeutics from an “overweight” rating to a “neutral” rating in a report on Tuesday, January 21st. Scotiabank dropped their price target on shares of Keros Therapeutics from $44.00 to $41.00 and set a “sector outperform” rating for the company in a research note on Thursday, January 16th. TD Cowen lowered shares of Keros Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Finally, Wells Fargo & Company decreased their price objective on Keros Therapeutics from $28.00 to $26.00 and set an “overweight” rating for the company in a report on Thursday, February 27th. Six equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $42.33.

Keros Therapeutics Price Performance

Shares of Keros Therapeutics stock opened at $10.19 on Tuesday. The company’s 50 day moving average price is $11.14 and its two-hundred day moving average price is $33.97. The firm has a market capitalization of $413.33 million, a P/E ratio of -1.96 and a beta of 1.39. Keros Therapeutics has a fifty-two week low of $9.71 and a fifty-two week high of $72.37.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($1.14) earnings per share for the quarter, beating the consensus estimate of ($1.36) by $0.22. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The company had revenue of $3.04 million for the quarter, compared to the consensus estimate of $37.32 million. On average, analysts expect that Keros Therapeutics will post -4.74 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. boosted its position in shares of Keros Therapeutics by 5.4% during the 4th quarter. Vanguard Group Inc. now owns 1,957,109 shares of the company’s stock valued at $30,981,000 after purchasing an additional 100,691 shares in the last quarter. Braidwell LP boosted its holdings in shares of Keros Therapeutics by 167.9% during the 4th quarter. Braidwell LP now owns 1,894,439 shares of the company’s stock worth $29,989,000 after buying an additional 1,187,199 shares in the last quarter. Darwin Global Management Ltd. boosted its holdings in shares of Keros Therapeutics by 10.7% during the 4th quarter. Darwin Global Management Ltd. now owns 1,687,135 shares of the company’s stock worth $26,707,000 after buying an additional 163,403 shares in the last quarter. Point72 Asset Management L.P. grew its position in shares of Keros Therapeutics by 155.9% during the 3rd quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company’s stock worth $55,025,000 after buying an additional 577,220 shares during the period. Finally, Millennium Management LLC increased its stake in shares of Keros Therapeutics by 53.3% in the 4th quarter. Millennium Management LLC now owns 878,159 shares of the company’s stock valued at $13,901,000 after acquiring an additional 305,169 shares in the last quarter. 71.56% of the stock is owned by institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.